Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL387795 | 0.86 | GPR119 (0.57) | GPR119ALDH1A1HTTNAMPT | |
| SCHEMBL386058 | 0.86 | GPR119 (0.51) | GPR119TBK1PRKAA2 | |
| SCHEMBL5048800 | 0.85 | GPR119 (0.56) | GPR119TBK1 | |
| SCHEMBL14454758 | 0.84 | SCN9A (0.47) | GPR119TBK1ALDH1A1CYP3A4PRKAA2 | |
| SCHEMBL389004 | 0.82 | GPR119 (0.59) | GPR119TBK1 | |
| SCHEMBL389472 | 0.82 | GPR119 (0.64) | GPR119CYP3A4 | |
| SCHEMBL388020 | 0.82 | GPR119 (0.71) | GPR119 | |
| SCHEMBL389376 | 0.81 | GPR119 (0.50) | GPR119TBK1NAMPTPKM | |
| SCHEMBL385945 | 0.80 | GPR119 (0.59) | GPR119TBK1 | |
| SCHEMBL389358 | 0.79 | GPR119 (0.49) | GPR119TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4777244-B2 | — | — | 2011-09-21 | — | — | JP | claimed |
| US-20110112060-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | claimed |
| US-7838525-B2 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | claimed |
| EP-1644357-B9 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2010-03-24 | — | — | EP | claimed |
| US-7470699-B2 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | claimed |
| EP-1923390-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2008-05-21 | — | — | EP | claimed |
| EP-1644357-B1 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2007-12-12 | — | — | EP | claimed |
| JP-2007528856-A | — | — | 2007-10-18 | — | — | JP | claimed |
| US-20070155763-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the phophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | claimed |
| EP-1644357-A1 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005007647-A9 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2005-04-07 | — | — | WO | claimed |
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | claimed |
| WO-2005007647-A1 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-8546429-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546429-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546429-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-1644357-A1 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005007647-A9 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005007647-A1 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112060-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | CYP7A1, CYP27A1, SULT2A1 | GPR119 25/4885TBK1 4582/4885ALDH1A1 163/4885 |
| US-20070155763-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the phophylaxis and treatment of disorders related thereto | CYP27A1, CYP11B2, CYP11B1 | GPR119 6/4885TBK1 4245/4885ALDH1A1 515/4885 |
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, SULT2A1 | GPR119 13/4885TBK1 4426/4885ALDH1A1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.